Ifosfamide-induced encephalopathy: Brand-name (HOLOXAN®) vs generic formulation (IFOSFAMIDE EG®).
Fiche publication
Date publication
mars 2019
Journal
Journal of clinical pharmacy and therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Dr RIOS Maria
Tous les auteurs :
Chambord J, Henny F, Salleron J, Hombourger B, Lider P, Vigneron J, Demore B, Vallance C, Rios M
Lien Pubmed
Résumé
Two forms of ifosfamide are commercially available in France: HOLOXAN® (brand-name drug) and IFOSFAMIDE EG® (generic drug). Following the marketing launch of the generic drug, there has been a significant increase in cases of ifosfamide-induced encephalopathy reported in France. Our objective is to compare the incidence of ifosfamide-induced encephalopathy in adult patients treated with HOLOXAN® or IFOSFAMIDE EG®.
Mots clés
Ifosfamide-induced encephalopathy, generic, ifosfamide formulation, risk factors
Référence
J Clin Pharm Ther. 2019 Mar 4;: